Trial ID or NCT#

NCT00657280

Status

NOT RECRUITING

Purpose

This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.

Official Title

Effect of Sitagliptin on Insulin Resistance and Myocardial Metabolism in Heart Failure

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michael B. Fowler, MB, FRCP
Cardiologist
Professor of Medicine (Cardiovascular) at the Stanford University Medical Center
Ronald Witteles, MD
Cardiologist, Heart failure cardiologist
Associate Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Ronald Witteles, MD
(650) 498-4343